Icon	Function
💬	A pop-up explanation appears when you mouse-over the text beside this icon. Also, an explanation window appears when you click this icon.
	The links beside this icon are links to external sites.
	Clicking this icon sorts the table by the item with this icon (Numerical or alphabetical order). Each click toggles between ascending and descending order.
	A text longer than 100 characters is fully displayed or collapsed.
	The contents of the displayed table are downloaded as a file named "table.csv".

DR info

Clinical trials : 7 / Drugs : 25 - (DrugBank : 10) / Drug target genes : 19 - Drug target pathways : 64

Drugs, Primary sponsors and Trial info (Enrollment year, Phase, Trial ID, Countries)

ALA
   Department of Hematolgy and Rheumatology, Tohoku University Graduate School of Medicine
      2016   -   JPRN-UMIN000023490   Japan
Allogeneic bone marrow transplantation
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
Aminolevulinic acid
   Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University
      2016   -   JPRN-UMIN000021407   Japan
Biospecimen collection
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
Bone marrow aspiration
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
Bone marrow biopsy
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
Computed tomography
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
Deferasirox
   NOVARTIS FARMA
      2010   -   EUCTR2010-021062-29-IT   Greece;Italy;United Kingdom
   Novartis Pharma Services AG
      2011   -   EUCTR2010-021062-29-GR   Greece;Italy;United Kingdom
      2010   -   EUCTR2010-021062-29-GB   Greece;Italy;United Kingdom
      2008   Phase 2   EUCTR2007-000766-20-GB   Italy;United Kingdom
Deferoxamine
   NOVARTIS FARMA
      2010   -   EUCTR2010-021062-29-IT   Greece;Italy;United Kingdom
   Novartis Pharma Services AG
      2008   Phase 2   EUCTR2007-000766-20-GB   Italy;United Kingdom
Deferoxamine mesilate
   Novartis Pharma Services AG
      2011   -   EUCTR2010-021062-29-GR   Greece;Italy;United Kingdom
      2010   -   EUCTR2010-021062-29-GB   Greece;Italy;United Kingdom
Desferal
   NOVARTIS FARMA
      2010   -   EUCTR2010-021062-29-IT   Greece;Italy;United Kingdom
   Novartis Pharma Services AG
      2011   -   EUCTR2010-021062-29-GR   Greece;Italy;United Kingdom
      2008   Phase 2   EUCTR2007-000766-20-GB   Italy;United Kingdom
DFO
   Novartis Pharma Services AG
      2011   -   EUCTR2010-021062-29-GR   Greece;Italy;United Kingdom
      2010   -   EUCTR2010-021062-29-GB   Greece;Italy;United Kingdom
      2008   Phase 2   EUCTR2007-000766-20-GB   Italy;United Kingdom
Echocardiography
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
Exjade
   NOVARTIS FARMA
      2010   -   EUCTR2010-021062-29-IT   Greece;Italy;United Kingdom
   Novartis Pharma Services AG
      2011   -   EUCTR2010-021062-29-GR   Greece;Italy;United Kingdom
      2010   -   EUCTR2010-021062-29-GB   Greece;Italy;United Kingdom
      2008   Phase 2   EUCTR2007-000766-20-GB   Italy;United Kingdom
Fludarabine phosphate
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
ICL670
   Novartis Pharma Services AG
      2011   -   EUCTR2010-021062-29-GR   Greece;Italy;United Kingdom
      2010   -   EUCTR2010-021062-29-GB   Greece;Italy;United Kingdom
      2008   Phase 2   EUCTR2007-000766-20-GB   Italy;United Kingdom
Lapine T-lymphocyte immune globulin
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
Methotrexate
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
Multigated acquisition scan
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
Peripheral blood stem cell transplantation
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
Phosphate
   Department of Hematolgy and Rheumatology, Tohoku University Graduate School of Medicine
      2016   -   JPRN-UMIN000023490   Japan
   Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University
      2016   -   JPRN-UMIN000021407   Japan
Quality-OF-life assessment
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
Tacrolimus
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
Treosulfan
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
X-RAY imaging
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States